Literature DB >> 21509875

Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI.

Matthias Eiber1, Konstantin Holzapfel, Carl Ganter, Kathrin Epple, Stephan Metz, Hans Geinitz, Hubert Kübler, Jochen Gaa, Ernst J Rummeny, Ambros J Beer.   

Abstract

PURPOSE: To evaluate the principal methodological aspects of whole-body magnetic resonance imaging (MRI) including diffusion-weighted imaging (DWI) with background suppression using a time-optimized protocol for restaging of prostate cancer patients in a technical feasibility study.
MATERIALS AND METHODS: Seventeen patients underwent MRI at 1.5T from the base of the skull to the proximal thigh using axial T1-weighted (T1w), T2w short-tau inversion recovery (STIR), and DWI (b-values: 50 and 500 s/mm(2)) and sagittal T1w and T2w STIR of the spine. Apparent diffusion coefficient (ADC) values of liver, spleen, kidney, muscle, and bone were measured. Image quality in DWI was assessed by using a scale from 0-9. Contrast-to-noise ratios (CNRs) of lymph node and bone metastases were determined in T1w, T2w STIR, and DWI. Bone metastases were further subclassified according to their Hounsfield units (HU) in computed tomography (CT).
RESULTS: Mean acquisition and mean room times were 66:20 and 75:21 minutes, respectively. ADC values of normal organs showed good concordance with reported data. Good to excellent image quality was observed for DWI (mean scores 7.41-8.00) with the exception of the neck (mean score 4.76). CNR of DWI (b-value 50 s/mm(2) ) for lymph node metastases was clearly superior compared to all other sequences. For bone metastases T1w performed significantly better for sclerotic lesions (HU > 600), DWI (b-value 50 s/mm(2) ) for nonsclerotic lesion (HU < 300).
CONCLUSION: In patients with recurrent prostate cancer a whole-body MR protocol including DWI is technically robust. Due to the high CNR of DWI compared to T1w and T2w STIR, detection of malignant lesions should be facilitated by DWI, except for sclerotic bone metastases.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21509875     DOI: 10.1002/jmri.22542

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  30 in total

1.  Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F] F and [18F]FDG: a Focus on Skeletal Lesions.

Authors:  Ida Sonni; Ryogo Minamimoto; Lucia Baratto; Sanjiv S Gambhir; Andreas M Loening; Shreyas S Vasanawala; Andrei Iagaru
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

2.  Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.

Authors:  Michael A Jacobs; Katarzyna J Macura; Atif Zaheer; Emmanuel S Antonarakis; Vered Stearns; Antonio C Wolff; Thorsten Feiweier; Ihab R Kamel; Richard L Wahl; Li Pan
Journal:  Acad Radiol       Date:  2018-04-04       Impact factor: 3.173

3.  Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy.

Authors:  Nicola L Robertson; Evis Sala; Matthias Benz; Jonathan Landa; Peter Scardino; Howard I Scher; Hedvig Hricak; Hebert A Vargas
Journal:  J Urol       Date:  2017-02-16       Impact factor: 7.450

4.  Role of whole-body diffusion-weighted MRI in detecting bone metastasis.

Authors:  Riccardo Del Vescovo; Giulia Frauenfelder; Francesco Giurazza; Claudia Lucia Piccolo; Roberto Luigi Cazzato; Rosario Francesco Grasso; Emiliano Schena; Bruno Beomonte Zobel
Journal:  Radiol Med       Date:  2014-03-18       Impact factor: 3.469

Review 5.  The emerging role of diffusion-weighted MRI in prostate cancer management.

Authors:  Edward M Lawrence; Vincent J Gnanapragasam; Andrew N Priest; Evis Sala
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

6.  Improved short tau inversion recovery (iSTIR) for increased tumor conspicuity in the abdomen.

Authors:  Ananth J Madhuranthakam; Karen S Lee; Aya Yassin; Jean H Brittain; Ivan Pedrosa; Neil M Rofsky; David C Alsop
Journal:  MAGMA       Date:  2013-09-20       Impact factor: 2.310

7.  Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.

Authors:  A J Conde-Moreno; G Herrando-Parreño; R Muelas-Soria; J Ferrer-Rebolleda; R Broseta-Torres; M P Cozar-Santiago; F García-Piñón; C Ferrer-Albiach
Journal:  Clin Transl Oncol       Date:  2016-10-31       Impact factor: 3.405

8.  Spinal metastasis: diagnosis, management and follow-up.

Authors:  Mahmud Mossa-Basha; Peter C Gerszten; Sten Myrehaug; Nina A Mayr; William Tc Yuh; Pejman Jabehdar Maralani; Arjun Sahgal; Simon S Lo
Journal:  Br J Radiol       Date:  2019-07-25       Impact factor: 3.039

9.  Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients.

Authors:  Matthias M Heck; Michael Souvatzoglou; Margitta Retz; Roman Nawroth; Hubert Kübler; Tobias Maurer; Mark Thalgott; Bettina M Gramer; Gregor Weirich; Ina-Christine Rondak; Ernst J Rummeny; Markus Schwaiger; Jürgen E Gschwend; Bernd Krause; Matthias Eiber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-03       Impact factor: 9.236

10.  Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?

Authors:  Hebert Alberto Vargas; Alexandre G Martin-Malburet; Toshikazu Takeda; Renato B Corradi; James Eastham; Andreas Wibmer; Evis Sala; Michael J Zelefsky; Wolfgang A Weber; Hedvig Hricak
Journal:  Urol Oncol       Date:  2016-06-23       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.